Plain-English translation of NCT07319871 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostatic Neoplasms research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing two medications used together: (JNJ-78278343), which trains your immune cells to fight prostate cancer, and , which helps remove barriers that prevent your immune system from working. Researchers want to find the right dose of these medications when given together, and then confirm whether this combination is safe and whether it can slow or shrink advanced prostate cancer.
Advanced prostate cancer that has stopped responding to hormone therapy (castration-resistant prostate cancer) is very difficult to treat, and many patients need better options. This trial explores whether combining an immune-boosting approach with a drug that removes immune blockades could offer a new, more effective treatment path.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
The trial has two parts. In Part 1, researchers gradually increase the doses of the two medications given together to find the safest and most effective combination dose. In Part 2, all participants receive that recommended dose to confirm it is safe and whether it helps fight the cancer. You will visit the research site regularly for blood tests, imaging scans, and check-ins to monitor how you are responding and any side effects you may experience.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States
United Kingdom